Last reviewed · How we verify

Marinol — Competitive Intelligence Brief

Marinol (Marinol) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed N-arachidonyl glycine receptor, Cannabinoid receptor 2, Fatty-acid amide hydrolase 1 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Marinol (Marinol) — Jazz Pharmaceuticals.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Marinol TARGET Marinol Jazz Pharmaceuticals marketed N-arachidonyl glycine receptor, Cannabinoid receptor 2, Fatty-acid amide hydrolase 1
tetrahydrocannabinol tetrahydrocannabinol Wageningen University marketed N-arachidonyl glycine receptor, Cannabinoid receptor 2, Fatty-acid amide hydrolase 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Marinol — Competitive Intelligence Brief. https://druglandscape.com/ci/marinol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: